###### 

Main baseline characteristics by presence of neurocognitive impairment and type of antiretroviral therapy

                                                 Impaired cognitive functioning                     Normal cognitive functioning                                         
  ---------------------------------------------- -------------------------------- ----------------- ------------------------------ ------------------ ------------------ ------
  Age, mean (DS)                                 49.5±8.6                         40.1±8.0          0.03                           48.6±9.2           46.6±3.4           0.49
  Gender: male, n (%)                            5 (50)                           5 (62.5)          0.60                           7 (77.8)           8 (66.7)           0.57
  HCV antibody +, n (%)                          3 (30)                           2 (25)            0.53                           4 (44.4)           4 (33.3)           0.67
  CD4 nadir, median (IQR)                        210 (71--323)                    73.5 (14--221)    0.17                           204 (187--309)     178 (59--284)      0.08
  Time since HIV+, median (IQR)                  15.6 (12.9--17.9)                9.9 (4.6--20.5)   0.18                           16 (13.2--22.3)    14.9 (8.6--20.9)   0.45
  Time of HIV-suppression, median (IQR)          9.1 (6.3--11.2)                  3.4 (3--5.6)      0.01                           5.5 (4.4--11)      7.1 (4.6--11.4)    0.73
  Time on antiretroviral therapy, median (IQR)   13.2 (12--15)                    5.9 (3.8--13.9)   0.01                           12.7 (7.2--16.7)   10.3 (6.3--16.5)   0.73
